Clinical Trials Directory

Trials / Completed

CompletedNCT04461756

Safety and Pharmacokinetics of Vaped Cannabis in Healthy Volunteers

A Phase I Exploratory Study to Assess the Pharmacokinetics of Single Inhaled Dose of Cannabis (Delta-9-Tetrahydrocannabinol / Cannabidiol) Administered by Vaporization Using a 4-Day Dose Titration In Healthy Male And Female Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Tetra Bio-Pharma · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The primary objective of this study was to evaluate the pharmacokinetics (PK) of THC, 11-OH-THC and CBD following a single inhaled dose of PPP001 administered by vaporization. The secondary objective of this study was to determine the safety and tolerability of THC and CBD after a single inhaled dose of PPP001 administered by vaporization in healthy volunteers.

Conditions

Interventions

TypeNameDescription
DRUGPPP001inhalation (vape)

Timeline

Start date
2018-11-01
Primary completion
2018-11-24
Completion
2018-11-24
First posted
2020-07-08
Last updated
2020-07-10

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT04461756. Inclusion in this directory is not an endorsement.

Safety and Pharmacokinetics of Vaped Cannabis in Healthy Volunteers (NCT04461756) · Clinical Trials Directory